Seeking Alpha

Biogen (BIIB) -0.8% following its Q1 miss, which was due to weaker-than-expected sales of its...

Biogen (BIIB) -0.8% following its Q1 miss, which was due to weaker-than-expected sales of its Avonex multiple sclerosis drug. Still, net profit edged up 3% to $302.7M. Biogen upgraded its 2012 outlook, and it now expects adjusted EPS of over $6.15 and revenue growth in the mid-single digits.

Check out Seeking Alpha’s new Earnings Center »

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs